Artiva CEO sells 61,888 shares to cover taxes

Artiva Biotherapeutics’ CEO reported an automatic sell-to-cover sale tied to RSU vesting, retaining over 1.47 million shares afterward.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Executive Officer Fred Aslan sold 61,888 shares of common stock on September 3, 2026 at a weighted average price of $11.1555 per share. The company states these automatic sales were made solely to cover tax withholding on vested restricted stock units, under a corporate sell-to-cover policy. Following the transaction, Aslan directly held 1,473,194 shares of Artiva common stock.

Insider Trade Summary

Net Seller: 61,888 shares

Net Sell 1 txn

Insider Aslan Fred

Role Chief Executive Officer

Sold 61,888 shs ($690K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	61,888	$11.1555	$690K

Holdings After Transaction: Common Stock — 1,473,194 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0270 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 61,888 shares Weighted average sale price: $11.1555 per share Sale price range: $11.0270–$11.1556 per share +1 more

4 metrics

Shares sold 61,888 shares Common stock sale by CEO on September 3, 2026

Weighted average sale price $11.1555 per share Common stock sold on September 3, 2026

Sale price range $11.0270–$11.1556 per share Range of prices for the 61,888 shares sold

Shares held after transaction 1,473,194 shares CEO’s direct Artiva common stock holdings post-sale

Key Terms

sell-to-cover, restricted stock units, weighted average sale price

3 terms

sell-to-cover financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"tax withholding obligations in connection with the vesting and release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $11.1555"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV disclose for CEO Fred Aslan?

Artiva Biotherapeutics disclosed that CEO Fred Aslan sold 61,888 shares of common stock on September 3, 2026 at a weighted average price of $11.1555 per share, in a transaction reported as a sale in the Form 4.

Why did the ARTV CEO sell 61,888 shares in this Form 4?

The company states the 61,888-share sale was made under a corporate sell-to-cover policy to satisfy the CEO’s tax withholding obligations arising from the vesting and release of restricted stock units, and that the sales were automatic and not at his discretion.

How many ARTV shares does the CEO hold after this reported sale?

After the reported transaction, CEO Fred Aslan directly held 1,473,194 shares of Artiva Biotherapeutics common stock, according to the Form 4’s post-transaction holdings figure.

At what prices were the ARTV shares sold in this insider transaction?

The Form 4 reports a weighted average sale price of $11.1555 per share, with individual sale prices ranging between $11.0270 and $11.1556 for the 61,888 shares sold.

Was the ARTV CEO’s sale under a Rule 10b5-1 trading plan?

No Rule 10b5-1 trading plan is indicated. The filing’s plan checkbox is not marked as being under such a plan, and the footnotes describe the sale as an automatic sell-to-cover for tax withholding on RSU vesting.

What type of security was involved in the ARTV insider sale?

The transaction involved Artiva Biotherapeutics common stock. The sale related to shares issued in connection with the vesting and release of restricted stock units held by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:03 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S		61,888(1)	D	$11.1555(2)	1,473,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0270 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)